AR054365A1 - Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos. - Google Patents

Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.

Info

Publication number
AR054365A1
AR054365A1 ARP060102193A ARP060102193A AR054365A1 AR 054365 A1 AR054365 A1 AR 054365A1 AR P060102193 A ARP060102193 A AR P060102193A AR P060102193 A ARP060102193 A AR P060102193A AR 054365 A1 AR054365 A1 AR 054365A1
Authority
AR
Argentina
Prior art keywords
alkyl
ring
het
independently selected
atom
Prior art date
Application number
ARP060102193A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36808854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054365(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0510852A external-priority patent/GB0510852D0/en
Priority claimed from GB0514177A external-priority patent/GB0514177D0/en
Priority claimed from GB0516295A external-priority patent/GB0516295D0/en
Priority claimed from GB0523861A external-priority patent/GB0523861D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR054365A1 publication Critical patent/AR054365A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un compuesto de la formula (1) donde R1 se selecciona de isopropilo, but-2-ilo, 1,1,1-trifluorprop-2-ilo, 1,3-difluorprop-2-ilo, but-1-in-3-ilo, 1-hidroxiprop-2-ilo, hidroxibut-3-ilo, 1-hidroxibut-2-ilo, tetrahidrofuranilo, tetrahidropiranilo, 1- metoxiprop-2-ilo, 1-metoxibut-2-ilo, 2-hidroxiprop-1-ilo, 2-metoxiprop-1-ilo, 2-hidroxibut-1-ilo, 2-metoxibut-1-ilo, 1-fluormetoxiprop-2-il, 1,1-difluormetoxiprop-2-ilo y 1-trifluormetoxiprop-2-ilo; HET-1 es un anillo heteroarilo ligado a C de 5 o 6 miembros, que contiene un átomo de N en la posicion 2, y opcionalmente, 1 o 2 heteroátomos adicionales de anillo seleccionados de manera independiente de O, N y S; en donde dicho anillo está opcionalmente sustituido en cualquier átomo de N, con un sustituyente seleccionado de R7, o en cualquier átomo de C disponible, con 1 o 2 sustituyentes seleccionados de modo independiente de R6; HET-2 es un anillo heterocíclico de 5 a 7 miembros, fusionado con el anillo benceno, que contiene 1, 2 o 3 heteroátomos de anillo seleccionados de modo independiente de O, S y N (siempre que no haya enlaces O-O, S-O o S-S dentro del anillo), donde cualquier átomo de S o C del anillo puede, en forma opcional, estar oxidado, y donde HET-2 está opcionalmente sustituido en cualquier átomo de N, con un sustituyente seleccionado de R2, o en cualquier átomo de C disponible, con 1 o 2 sustituyentes seleccionados de modo independiente de R3; R2 se selecciona de alquilo C1-4, cicloalquilo C3-6, bencilo, alquilcarbonilo C1-4, alquilsulfonilo C1-4, hidroxi-alquilo C1-4 y alcoxi C1-4-alquilo C1-4, R3 se selecciona de alquilo C1-4, cicloalquilo C3-6, alcoxi C1-4, hidroxi, F y Cl; R4 se selecciona de H, F y Cl; R6 se selecciona de manera independiente de alquilo C1-4, halo, hidroxialquilo C1-4, alcoxi C1-4-alquilo C1-4, alquilo C1-4S(O)p-alquilo C1-4, aminoalquilo C1-4, alquilamino C1-4-alquilo C1-4, di-alquilamino C1-4-alquilo C1-4 y HET-3; R7 se selecciona de manera independiente de alquilo C1-4, hidroxialquilo C1-4, alcoxi C1-4-alquilo C1-4, alquilo C1-4S(O)p-alquilo C1-4, aminoalquilo C1-4, alquilamino C1-4-alquilo C1-4, di-alquilamino C1-4-alquilo C1-4 y HET-3; HET-3 es un anillo heteroarilo no sustituido, ligado a C o N, de 5 o 6 miembros, que contiene 1, 2 o 3 heteroátomos de anillo seleccionados de modo independiente de O, N y S; p es (de manera independiente en cada aparicion) 0, 1 o 2; o una sal o un profármaco de dicho compuesto.
ARP060102193A 2005-05-27 2006-05-26 Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos. AR054365A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0510852A GB0510852D0 (en) 2005-05-27 2005-05-27 Chemical compounds
GB0514177A GB0514177D0 (en) 2005-07-09 2005-07-09 Chemical compounds
GB0516295A GB0516295D0 (en) 2005-08-09 2005-08-09 Chemical compounds
GB0523861A GB0523861D0 (en) 2005-11-24 2005-11-24 Chemical compounds

Publications (1)

Publication Number Publication Date
AR054365A1 true AR054365A1 (es) 2007-06-20

Family

ID=36808854

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102193A AR054365A1 (es) 2005-05-27 2006-05-26 Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.

Country Status (14)

Country Link
US (1) US7943607B2 (es)
EP (1) EP1891058A1 (es)
JP (1) JP2008545684A (es)
KR (1) KR20080011689A (es)
AR (1) AR054365A1 (es)
AU (1) AU2006250985A1 (es)
BR (1) BRPI0609892A2 (es)
CA (1) CA2609235A1 (es)
IL (1) IL186865A0 (es)
MX (1) MX2007014784A (es)
NO (1) NO20075626L (es)
TW (1) TW200714597A (es)
UY (1) UY29562A1 (es)
WO (1) WO2006125972A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280872A1 (en) * 2004-02-18 2008-11-13 Craig Johnstone Benzamide Derivatives and Their Use as Glucokinase Activating Agents
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
JP4651714B2 (ja) * 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2261216A3 (en) 2006-07-24 2011-12-14 F. Hoffmann-La Roche AG Pyrazoles as glucokinase activators
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT2197849E (pt) 2007-10-09 2013-04-23 Merck Patent Gmbh Derivados de n-(pirazole-3-il)-benzamida como ativadores de glucoquinase
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
CN102171213A (zh) 2008-08-04 2011-08-31 阿斯利康(瑞典)有限公司 吡唑并[3，4]嘧啶-4-基衍生物及其治疗糖尿病和肥胖症的用途
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
CA2774715C (en) 2009-07-27 2018-04-03 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
FR2964969B1 (fr) 2010-09-16 2012-08-24 Servier Lab Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
JP5792128B2 (ja) 2011-07-29 2015-10-07 富士フイルム株式会社 １，５−ナフチリジン誘導体又はその塩
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2781521A4 (en) 2011-10-19 2015-03-04 Kowa Co NOVEL COMPOUND OF SPIROINDOLINE AND THERAPEUTIC AGENT CONTAINING THE SAME
LT3043784T (lt) 2013-09-09 2019-08-12 Peloton Therapeutics, Inc. Arilo eteriai ir jų panaudojimo būdai
ES2737148T3 (es) * 2013-12-16 2020-01-10 Peloton Therapeutics Inc Análogos de sulfona y sulfoximina cíclicos y usos de los mismos
EP3267792A4 (en) 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US11872221B2 (en) 2020-01-31 2024-01-16 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator
AU2020426356A1 (en) * 2020-01-31 2022-08-25 Hua Medicine (Shanghai) Ltd. Treating treatment-resistant diabetes with glucokinase activator
KR20220136030A (ko) 2021-03-31 2022-10-07 오윤석 실시간 스트리밍 서비스를 이용한 부동산 중개 서버

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2750393A (en) * 1954-12-01 1956-06-12 Sterling Drug Inc Iodinated 5-henzamidotetrazoles and preparation thereof
US2967194A (en) * 1958-05-15 1961-01-03 Pennsalt Chemicals Corp 4-trifluoromethylsalicylamides
FR1526074A (fr) 1967-03-22 1968-05-24 Rech S Ind S O R I Soc D Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation
FR2088019A1 (en) 1970-05-08 1972-01-07 Rabot Ets David Esters of 2 and 6-substituted nicotinic acids - with vasomotor active
GB1352415A (en) 1970-05-03 1974-05-08 Boots Co Ltd Esters of substituted nicotine acids
CS173097B1 (es) 1972-12-01 1977-02-28
GB1400540A (en) * 1972-12-06 1975-07-16 Smith Kline French Lab Salicylamides and compositions thereof
US4009174A (en) * 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
FR2344284A1 (fr) * 1976-03-17 1977-10-14 Cerm Cent Europ Rech Mauvernay Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs
GB1588242A (en) 1977-10-28 1981-04-23 May & Baker Ltd N-(tetrazol-5-yl)-salicylamide derivatives
US4474792A (en) * 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
FR2493848B2 (fr) * 1980-11-07 1986-05-16 Delalande Sa Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique
JPS59139357A (ja) * 1983-01-28 1984-08-10 Torii Yakuhin Kk アミジン誘導体
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
JP2852659B2 (ja) 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
DE3822449A1 (de) 1988-07-02 1990-01-04 Henkel Kgaa Oxidationshaarfaerbemittel mit neuen kupplern
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5258407A (en) * 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5672750A (en) * 1994-12-16 1997-09-30 Eastman Chemical Company Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
FR2757852B1 (fr) * 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
KR20010014183A (ko) * 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
DE69826286T2 (de) * 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6114483A (en) 1997-08-27 2000-09-05 E. I. Du Pont De Nemours And Company Polymerization of olefins
JP4398585B2 (ja) 1997-11-12 2010-01-13 有限会社ケムフィズ レチノイドレセプター作用剤
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
WO1999038845A1 (en) * 1998-01-29 1999-08-05 Tularik Inc. Ppar-gamma modulators
DE19816780A1 (de) * 1998-04-16 1999-10-21 Bayer Ag Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6197798B1 (en) * 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
WO2001035950A2 (en) * 1999-11-18 2001-05-25 Centaur Pharmaceuticals, Inc. Benzamide therapeutics and methods for treating inflammatory bowel disease
EP1259485B1 (en) * 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
EP1132381A1 (en) 2000-03-08 2001-09-12 Cermol S.A. Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
WO2001083465A2 (en) * 2000-05-03 2001-11-08 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
CA2424522C (en) * 2000-11-22 2009-12-29 Yamanouchi Pharmaceutical Co., Ltd. Substituted benzene derivatives or salts thereof
BR0115999A (pt) * 2000-12-06 2003-09-30 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, sua utilização, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto
CN1289072C (zh) * 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
JPWO2002062775A1 (ja) 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CN1551866A (zh) * 2001-08-09 2004-12-01 СҰҩƷ��ҵ��ʽ���� 羧酸衍生物化合物及包含这些化合物为活性成分的药物
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1336607A1 (en) 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
DE60328671D1 (de) 2002-03-26 2009-09-17 Banyu Pharma Co Ltd Neue aminobenzamidderivate
AU2003252478A1 (en) * 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
JP4432901B2 (ja) 2003-02-26 2010-03-17 萬有製薬株式会社 ヘテロアリールカルバモイルベンゼン誘導体
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
WO2005048948A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
GB0327760D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
WO2005063738A1 (ja) 2003-12-29 2005-07-14 Banyu Pharmaceutical Co.,Ltd 新規２－へテロアリール置換ベンズイミダゾール誘導体
US20080280872A1 (en) * 2004-02-18 2008-11-13 Craig Johnstone Benzamide Derivatives and Their Use as Glucokinase Activating Agents
BRPI0507734A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR20070085371A (ko) * 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
US8859581B2 (en) 2005-04-25 2014-10-14 Merck Patent Gmbh Azaheterocyclic compounds as kinase inhibitors
US20080234273A1 (en) * 2005-07-09 2008-09-25 Mckerrecher Darren Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
JP4651714B2 (ja) * 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
JP2009504621A (ja) * 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
EP1928874A1 (en) * 2005-09-16 2008-06-11 AstraZeneca AB Heterobicyclic compounds as glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) * 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
CA2671535A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Novel crystalline compound useful as glk activator
CN102171213A (zh) * 2008-08-04 2011-08-31 阿斯利康(瑞典)有限公司 吡唑并[3，4]嘧啶-4-基衍生物及其治疗糖尿病和肥胖症的用途
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
WO2010116177A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity

Also Published As

Publication number Publication date
WO2006125972A1 (en) 2006-11-30
IL186865A0 (en) 2008-02-09
NO20075626L (no) 2007-12-18
MX2007014784A (es) 2008-02-19
US20090105214A1 (en) 2009-04-23
BRPI0609892A2 (pt) 2011-10-11
CA2609235A1 (en) 2006-11-30
AU2006250985A1 (en) 2006-11-30
TW200714597A (en) 2007-04-16
EP1891058A1 (en) 2008-02-27
US7943607B2 (en) 2011-05-17
UY29562A1 (es) 2006-12-29
JP2008545684A (ja) 2008-12-18
KR20080011689A (ko) 2008-02-05

Similar Documents

Publication Publication Date Title
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
AR048495A1 (es) Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
UY28756A1 (es) Compuestos
CO6160322A2 (es) Derivados de quinazolinona e isoquinolinona acetamida
ES2668775T3 (es) Compuestos tetracíclicos
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
ECSP088549A (es) Nuevos derivados de pirrol fusionado
AR053329A1 (es) Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
CO6220878A2 (es) Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo
PA8783601A1 (es) Derivados de piperidina/piperazina
AR012825A1 (es) Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos
PE20180500A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR053347A1 (es) Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
AR058984A1 (es) Derivados de ciclohexil piperazinil metanona
MX2010000658A (es) Derivados de pirimidina 934.
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
AR073565A1 (es) Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen
AR067996A1 (es) Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros.
PE20201068A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal